Regeneron Pharmaceuticals

This is the first study to test a new drug, REGN17372, in combination with an existing drug, linvoseltamab, in people with advanced multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose for the combination and see if…

This large study is testing a new drug combination (linvoseltamab, bortezomib, lenalidomide) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. It will compare this new combination, with and without the transplant, against the current st…

This study is testing an experimental drug called REGN13335 for adults with Pulmonary Arterial Hypertension (PAH), a serious lung and heart condition. The goal is to see if adding this new drug to a patient's current standard medications can better control the disease by reducing…

This study is testing if a cholesterol-lowering drug called alirocumab is safe and effective when given as a weekly injection instead of the usual schedule. It will involve 420 adults with high cholesterol. Researchers will measure how much the drug lowers 'bad' cholesterol and t…

This large Phase 3 study is testing two new injectable drugs, REGN7508 and REGN9933, to prevent strokes and blood clots in people with atrial fibrillation (an irregular heartbeat) who cannot safely take standard oral blood thinners. The study will compare these experimental drugs…

This study is testing whether an experimental drug called linvoseltamab can delay the development of active multiple myeloma better than an existing drug, daratumumab. It involves 270 people diagnosed with high-risk smoldering multiple myeloma, a condition that often progresses t…

This large study is testing two new antibody drugs, REGN7508 and REGN9933, to prevent life-threatening blood clots in people with narrowed leg arteries who just had surgery to improve blood flow. The study will compare these new drugs against both a standard blood thinner (rivaro…